Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EVMN vs DNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EVMN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–4 Matrix Metrics)

EVMN Overall Winner 6-Pillar Tally: EVMN 3 – 2 DNA (1 Tie) Matrix Metrics: EVMN 4 – 4 DNA

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Ginkgo Bioworks Holdings, Inc. (DNA) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). EVMN carries a Unified Composite Score of 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin), whereas DNA carries 56.0/100 (HOLD) at $8.50 (N/M Forward P/E, -202.5% operating margin).

  • Composite vs. Pillar Nuance: While DNA currently prints a higher short-term Unified Composite Score (56.0/100 HOLD vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -202.5% operating margin) and revenue trajectory (+0.0% vs. -5.7% YoY).
  • Technical & Structure Timing Caution: EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2); meanwhile DNA is in a Breakdown options structure phase (RSI 41.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EVMN vs DNA
EVMN US Equity Head-to-Head Winner
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 118% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $6.45 · SMA50: $7.47
DNA NYSE
Ginkgo Bioworks Holdings, Inc.
Biological Products, (No Disgnostic Substances)
$8.50
-11.55% 1D
Market Cap $623.0M
TTM Revenue $131M
Forward P/E N/M
Beta / 30D Vol 3.14β · 152% Vol
Unified Composite Score
56.0 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.0 · SMA20: $10.73 · SMA50: $10.32

6-Pillar Scorecard Institutional Category Breakdown (EVMN 3 – 2 DNA)

Columns: Metric · EVMN · DNA
1. Valuation Multiples DNA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 7.2x
2. Growth & Scale DNA
Revenue Growth (YoY) +0.0% -5.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $131M
Market Cap $315.5M $623.0M
3. Profitability & Quality EVMN
Gross Margin N/A 69.8%
Operating Margin 0.0% -202.5%
Net Profit Margin 0.0% -192.0%
Return on Equity (ROE) -69.5% -58.2%
4. Balance Sheet & Cash Flow EVMN
Cash Generation (TTM) -$75M -$174M
Cash Flow Margin N/A N/A
Net Cash / Leverage $52M Net Cash $313M Net Debt (1.01x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVMN
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 209.0% (53rd %ile) 119.2% (34th %ile)
Put/Call OI Skew N/A 0.13x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EVMN (4) vs DNA (4)
Institutional Metric EVMN DNA Criterion Row Edge
Market Capitalization
Scale
$315.5M $623.0M Larger Scale DNA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -5.7% Higher Growth EVMN
Operating Margin (TTM)
Profitability
0.0% -202.5% Higher Margin EVMN
Net Profit Margin
Profitability
0.0% -192.0% Higher Margin EVMN
Return on Equity (ROE)
Capital Efficiency
-69.5% -58.2% Higher ROE DNA
52-Week Range Position
Momentum
8% ($5–$33) 24% ($5–$18) Stronger Trend DNA
Beta / 30D Volatility
Risk Regime
1.05β · 118% Vol 3.14β · 152% Vol Lower Realized Risk EVMN
Unified Institutional Score
Composite Signal
30.0 / 100 (SELL) 56.0 / 100 (HOLD) Higher Composite DNA
Trailing 12M Revenue (USD)
Operating Scale
N/A $131M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 69.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 7.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$75M ($52M Net Cash) -$174M ($313M Net Debt (1.01x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVMN +54.56 pp
EVMN: +37.33% · DNA: -17.23%
3M Horizon DNA +80.24 pp
EVMN: -50.07% · DNA: +30.17%
6M Horizon DNA +82.9 pp
EVMN: -67.57% · DNA: +15.33%
1Y Horizon DNA +67.28 pp
EVMN: -61.03% · DNA: +6.25%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EVMN Revenue DNA Revenue EVMN Op. Margin DNA Op. Margin Margin Leader
FY2019 N/A $50M N/A -132.1% DNA
FY2020 N/A $80M N/A -178.8% DNA
FY2021 N/A $310M N/A -582.6% DNA
FY2022 N/A $480M N/A -462.4% DNA
FY2023 N/A $250M N/A -343.8% DNA
FY2024 $10M $230M -1000.2% -246.5% DNA
FY2025 $10M $170M -623.6% -185.3% DNA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EVMN SURGE
5d in phase · OBV ACCUMULATION
Current IV 209.0%
IV Percentile 53rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DNA BREAKDOWN
30d in phase · OBV DISTRIBUTION
Current IV 119.2%
IV Percentile 34th %ile
Put/Call OI Skew 0.13x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact DNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EVMN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $623.0M market capitalization and -202.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EVMN vs DNA Key Questions & Quantitative Answers

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Ginkgo Bioworks Holdings, Inc. (DNA) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). EVMN carries a Unified Composite Score of 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin), whereas DNA carries 56.0/100 (HOLD) at $8.50 (N/M Forward P/E, -202.5% operating margin). Composite vs. Pillar Nuance: While DNA currently prints a higher short-term Unified Composite Score (56.0/100 HOLD vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (4–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -202.5% operating margin) and revenue trajectory (+0.0% vs. -5.7% YoY). Technical & Structure Timing Caution: EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2); meanwhile DNA is in a Breakdown options structure phase (RSI 41.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DNA leads the Growth & Scale pillar: EVMN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DNA at -5.7% YoY revenue growth and +0.0% YoY earnings growth on $131M TTM revenue (69.8% gross margin, -202.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), EVMN cumulative revenue shifted +0.0% while DNA shifted +240.0%. In operating R&D and SG&A reinvestment, EVMN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DNA.

DNA screens cheaper on headline valuation multiples. EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVMN (-69.5% ROE) versus DNA (-58.2% ROE) capital efficiency.

In options market volatility and institutional positioning, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk). By comparison, DNA carries 119.2% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.14β · 152% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.